Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment

Sphera Funds added 374,847 shares of Syndax Pharmaceuticals in the fourth quarter. The quarter-end position value rose by $10.06 million, reflecting both trading and price movement.